布魯氏菌病疫苗市場- 類型（RB51、S19、B19 疫苗）、疫苗（DNA、亞單位、載體疫苗）、動物類型（牛、綿羊、山羊）、最終用戶（獸醫診所和醫院、動物護理中心）、全球預測（2024 - 2032）

Brucellosis Vaccine Market - Type (RB51, S19, B19 vaccines), Vaccine (DNA, Sub-unit, Vector Vaccines), Animal Type (Cattle, Sheep, Goat), End-user (Veterinary Clinics & Hospitals, Animal Care Centers), Global Forecast (2024 - 2032)

出版日期: 2024年05月20日 | 出版商:

Global Market Insights Inc. | 英文 154 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於全球家畜和動物疫苗接種工作不斷增加，2024 年至 2032 年間，全球布魯氏菌病疫苗市場複合年成長率將達到 4.9%。布魯氏菌病是一種影響多種動物的傳染病，對農業和公共衛生構成重大風險。在非洲、亞洲和拉丁美洲部分地區等牲畜數量較多的地區，政府和農業組織正在加強疫苗接種計劃，以控制和根除布魯氏菌病。這些措施是出於保護動物健康、加強糧食安全和防止人畜共患病傳播給人類的需要而推動的。例如，2023 年 9 月，昌迪加爾政府根據聯邦政府國家動物疾病控制計劃，為 21,000 多頭牲畜接種了口蹄疫 (FMD) 疫苗。這項計劃包括牛、水牛、山羊、綿羊和豬，免費提供口蹄疫和布魯氏菌病疫苗接種。

在已開發地區，嚴格的動物健康法規和生物安全措施支持了正在進行的疫苗接種工作。隨著人們對布魯氏菌病影響的認知不斷增強，公共和私營部門都在投資先進的疫苗開發和分發。全球對全面疫苗接種策略的推動正在推動市場成長，確保更好地控制布魯氏菌病，並支持永續的牲畜管理實踐。

整個布魯氏菌病疫苗產業根據類型、疫苗、動物類型、最終用戶和地區進行分類。

根據類型，S19疫苗領域的布魯氏菌病疫苗市場收入將在2024年至2032年實現令人稱讚的複合年成長率。其他動物的布魯氏菌病疫情。它能夠誘導強烈的免疫反應並降低疾病盛行率，這對於預防感染和保障動物健康至關重要。隨著農業產業和政府優先考慮疾病控制和公共衛生，S19 疫苗的採用正在推動市場需求的增加。這一激增反映了全球對改善牲畜管理和減輕布魯氏菌病影響的承諾。

在疫苗方面，次單位疫苗部分將在2024年至2032年顯著增加。它們的精確性和不良反應風險的降低使它們對牲畜疫苗接種計劃極具吸引力。隨著農業實踐的進步和有效疾病管理需求的成長，亞單位疫苗正在成為控制布魯氏菌病爆發的首選。它們的開發和採用促進了市場需求的顯著成長，反映出向更安全、更有效率的疫苗接種解決方案的轉變。

2024年至2032年，歐洲布魯氏菌病疫苗市場將呈現顯著的複合年成長率。。隨著農民和政府尋求有效的解決方案來管理和根除布魯氏菌病，歐盟強力的動物健康政策和疫苗接種計劃資金推動了市場成長。由於該地區注重維持動物福利和食品安全的高標準，歐洲的布魯氏菌病疫苗市場正經歷顯著的擴張和投資。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Ceva
Colorado Serum Company
Creative Biolabs
CZ Vaccines
Fivet Animal Health
Hester Biosciences Limited
Indian Immunologicals Ltd.
Jordan Bio-industries Center
Laboratories Tornel
Merck & Co., Inc.
VETAL Animal Health Products Inc.
Veterinary Technologies Corporation

簡介目錄

Product Code: 9544

Global Brucellosis Vaccine Market will witness 4.9% CAGR between 2024 and 2032 due to rising vaccination efforts for livestock and animals globally. Brucellosis, a contagious disease affecting various animals, poses significant risks to agricultural industries and public health. In regions with high livestock populations, such as parts of Africa, Asia, and Latin America, governments and agricultural organizations are intensifying vaccination programs to control and eradicate Brucellosis. These initiatives are driven by the need to protect animal health, enhance food security, and prevent zoonotic transmission to humans. For instance, in September 2023, the Chandigarh administration vaccinated more than 21,000 livestock against foot and mouth disease (FMD) under the National Animal Disease Control Programme of the Union government. This initiative, which included cattle, buffalo, goats, sheep, and pigs, provided free vaccinations against both FMD and Brucellosis.

In developed regions, ongoing vaccination efforts are bolstered by stringent animal health regulations and biosecurity measures. As awareness of Brucellosis's impact grows, both public and private sectors are investing in advanced vaccine development and distribution. This global push towards comprehensive vaccination strategies is fueling market growth, ensuring better control of Brucellosis, and supporting sustainable livestock management practices.

The overall Brucellosis Vaccine Industry is classified based on the type, vaccine, animal type, end-user, and region.

Based on type, the brucellosis vaccine market revenue from the S19 vaccines segment will register a commendable CAGR from 2024 to 2032. The S19 vaccine, known for its efficacy and long-lasting protection, is widely used to control brucellosis outbreaks among cattle and other animals. Its ability to induce strong immune responses and reduce disease prevalence makes it crucial for both preventing infections and safeguarding animal health. As agricultural industries and governments prioritize disease control and public health, the adoption of S19 vaccines is driving increased market demand. This surge reflects the global commitment to improving livestock management and mitigating brucellosis impacts.

In terms of vaccine, the sub-unit vaccines segment will witness an appreciable growth from 2024 to 2032. Subunit vaccines, which contain only specific antigens from the Brucella bacterium, provide targeted protection without the risk of causing disease. Their precision and reduced risk of adverse reactions make them highly attractive for livestock vaccination programs. As agricultural practices advance and the need for effective disease management grows, subunit vaccines are becoming a preferred choice for controlling brucellosis outbreaks. Their development and adoption are contributing to a significant rise in market demand, reflecting a shift towards safer and more efficient vaccination solutions.

Europe brucellosis vaccine market will exhibit a notable CAGR from 2024 to 2032. European countries are prioritizing vaccination to prevent brucellosis outbreaks, which can impact both animal health and public safety. The European Union's robust animal health policies and funding for vaccination programs drive market growth as farmers and governments seek effective solutions to manage and eradicate brucellosis. As the region focuses on maintaining high standards of animal welfare and food security, the brucellosis vaccine market in Europe is experiencing significant expansion and investment.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of brucellosis
  - 3.2.1.2 Increasing livestock production
  - 3.2.1.3 Rising awareness about zoonotic diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements for animal vaccines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 RB51 vaccines
5.3 S19 vaccines
5.4 B19 vaccines
5.5 Other types

Chapter 6 Market Estimates and Forecast, By Vaccine, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 DNA vaccines
6.3 Subunit vaccines
6.4 Vector vaccines
6.5 Recombinant vaccines

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cattle
7.3 Sheep
7.4 Goat
7.5 Other animal type

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Veterinary clinics & hospitals
8.3 Animal care centers
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa